Table 4.
Overall characteristics of study participants.
| Characteristic | Total (n = 152) | Viral Suppression (<400 copies/mL) on ART (n = 94) | Viral unsuppressed (>400 copies/mL) on ART (n = 27) | Treatment-naïve n = 31 | p value |
|---|---|---|---|---|---|
| Gender, n (%) | |||||
| Female | 97 (63.8) | 63 (67.0) | 14 (51.9) | 20 (64.5) | 0.4 |
| Male | 53 (34.9) | 29 (30.9) | 13 (48.1) | 11 (35.5) | |
| unknown | 2(1.3) | 2 (2.1) | 0 | 0 | |
| Age [n (%)] | |||||
| <30 | 16 (10.5) | 7 (7.4) | 2(7.5) | 7 (22.6) | 0.1 |
| 30–45 | 77 (50.7) | 48 (51.1) | 12(44.4) | 17 (54.8) | |
| >45 | 56(36.8) | 37(39.4) | 12 (44.4) | 7 (22.6) | |
| Unknown | 3(2.0) | 2(2.1) | 1(3.7) | 0 | |
| Treatment type (n = 121), n (%) | |||||
| Atripla (EFV/TDF/FTC) | 62 (51.2) | 47 (50.0) | 15 (55.6) | <0.01 | |
| Unknown | 35 (28.9) | 28 (29.8) | 7 (25.9) | n/a | |
| TLD (DTG/3TC/TDF) | 19 (15.8) | 15(16.0) | 4(14.8) | ||
| Dovato (DTG/3TC) | 4 (3.3) | 3 (3.2) | 1 (3.7) | ||
| Truvada (FTC/TDF) | 1 (0.8) | 1 (1.0) | 0 | ||
| Country of origin n (%) | |||||
| Zimbabwe | 142 (93.4) | 88 (93.6) | 25 (92.6) | 29 (93.5) | 0.5 |
| Other | 8 (5.3) | 4 (4.3) | 2 (7.4) | 2 (6.5) | |
| Unknown | 2 (1.3) | 2(2.1) | |||
| HIV-1 RNA (log10 Copies/mL), Median (Q1, Q3) | 1.6 (1.6–3.6) | 1.6 (1.6–1.6) | 4.4 (3.7–4.8) | 3.8 (2.2–4.7) | <0.01 |
Demographical, clinical, and virological characteristics of the study group, stratified by ART status and level of suppression. Continuous variables values are expressed as median and first and third quartiles (Q1, Q3) (25–75 percentiles) and categorical variables are displayed as the number of cases (percentage and confidence interval-95% in parentheses). VL (viral load in Log10). Other (Malawi, South Africa, Tanzania, Mozambique, and Zambia).